Business Context and Reporting Period
This Form 8-K was filed by NextCure, Inc. on February 24, 2021, reporting events occurring on February 21, 2021. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Beltsville, Maryland. Its common stock trades on the Nasdaq Global Select Market under the symbol NXTC.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the resignation of Dr. Briggs Morrison from the Board of Directors, effective April 1, 2021. The Company explicitly stated that the resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies were disclosed in this report other than the standard disclosure regarding the director's departure.
Key Facts for Investor Verification
- Dr. Briggs Morrison resigned from the Board of Directors effective April 1, 2021.
- The resignation was voluntary and unrelated to any disagreement with the Company.
- The report was signed by Steven P. Cobourn, Chief Financial Officer.
- No financial results or operational metrics are included in this specific filing.